Too much suc­cess? A boom­ing biotech pipeline will spur in­tense ri­val­ries — an­a­lyst

Over the last 5 years biotech has been boom­ing. And that could pose a big prob­lem for every­one in­volved.

Like oth­ers in the in­dus­try, Leerink’s Ge­of­frey Porges hasn’t over­looked ev­i­dence that every hot new tar­get in drug dis­cov­ery quick­ly at­tracts a clus­ter of bio­phar­ma com­pa­nies. At ASH, he count­ed at least a dozen BC­MA drugs in the pipeline. So Porges de­cid­ed to quan­ti­fy the trend, break­ing it down in­to 15 ther­a­peu­tic ar­eas.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER